OQROGet OQRO Pro
Politician trade (House)

Bridgebio Pharma (BBIO)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Cisneros (CA31) disclosed a purchase of Bridgebio Pharma in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
28 days
Disclosure lag
Traded
May 11, 2026
Disclosed
Jun 8, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 3, 2026CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  2. Mar 18, 2026CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  3. Mar 19, 2026CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  4. Apr 29, 2026CongressDisclosed purchase of BBIO — reported range $1,001 - $15,000
  5. May 6, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  6. May 7, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement
  7. May 11, 2026 · this disclosureCongressDisclosed purchase of BBIO — reported range $1,001 - $15,000

What came next

  1. Jun 22, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 22, 2026, Dr. Randal W. Scott notified BridgeBio Pharma, Inc. (the “Company”), of his resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of his term as a Class I director, effective as of June 22, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
  2. Jul 1, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 3 more items)
  3. Aug 10, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 13, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Bridgebio Pharma

For Bridgebio Pharma, OQRO holds 17 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BBIO page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

How this filing works

Other disclosures at Bridgebio Pharma

Everything OQRO holds on this company is on its BBIO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data